Shrinking BridgeBio confirms layoffs, details out-licensing plans for its ‘restructuring initiative’

In the wake of BridgeBio’s Phase III fail for its lead drug late last year, the company has been tight-lipped about its “restructuring initiative.” …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Shrink­ing Bridge­Bio con­firms lay­offs, de­tails out-li­cens­ing plans for its ‘re­struc­tur­ing ini­tia­tive’